06 September 2021
: Case report 
A Rare Case of Factor VII Inhibitor in a Patient Presenting with Primary Splenic Marginal Zone Lymphoma
Rare disease
Kendra Naismith1CDEF, Pat A. Allevato2B, Caroline Hamm13ABDF*DOI: 10.12659/AJCR.932704
Am J Case Rep 2021; 22:e932704
Table 1. Therapy timeline. An overview of the therapies employed in the first 2 months of treatment along with the associated international normalized ratio, platelet, and factor VII levels. “xx” indicates days when plasmapheresis was conducted.
| Date | Plasma-pheresis | IVIG (g) | Solumedrol (mg) | FFP units | Rituximab (mg) | INR | Platelet count | FVII (0.62–1.46 U/mL) |
|---|---|---|---|---|---|---|---|---|
| Feb 19 | 3.2 | 99 | ||||||
| Feb 20 | 110 | |||||||
| Feb 22 | 3.1 | |||||||
| Feb 23 | 2 | 2.9 | 112 | |||||
| Feb 24 | 4 | 3.1 | 114 | |||||
| Feb 25 | 100 | 2 | 2.9 | 104 | ||||
| Feb 26 | 620 | 3.8 | 101 | |||||
| Feb 27 | 50 | 8 | 2.9 | 14 | ||||
| Feb 28 | 50 | 3.1 | 31 | |||||
| Feb 29 | 3.1 | 0.09 | ||||||
| Mar 1 | 50 | 50 | 3.3 | 43 | ||||
| Mar 2 | 40 | 3.2 | 67 | |||||
| Mar 3 | xx | 40 | 3.4 | 79 | ||||
| Mar 4 | xx | 3.4 | 100 | |||||
| Mar 5 | xx | 3.2 | 105 | |||||
| Mar 5 | xx | 3.2 | 96 | |||||
| Mar 6 | xx | 2.7 | ||||||
| Mar 7 | xx | 2.5 | ||||||
| Mar 8 | 1.2 | 0.5 | ||||||
| Mar 9 | 2.1 | |||||||
| Mar 11 | 2.2 | 111 | ||||||
| Mar 12 | 620 | 2.2 | 63 | |||||
| Mar 13 | 2.2 | 56 | 0.73 | |||||
| INR – international normalized ratio; FFP – fresh frozen plasma; IVIG – intravenous immune globulin; FVII – factor VII. | ||||||||